drugset / Trial / NCT01415531

Study of the Efficacy and Safety of Nebivolol in Younger Patients (18 - 54 Years)

NCT01415531

Phase 4 Completed 641 enrolled Forest Laboratories
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to assess the efficacy, safety, and tolerability of 8 weeks of therapy with nebivolol in comparison to placebo in younger patients 18 - 54 years of age with stage 1 or stage 2 essential hypertension.

Timeline

Start
2011-08
Primary completion
2012-03
Completion
2012-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Nebivolol Other / unclassified 5 mg Oral
Subject Nebivolol Other / unclassified 10 mg Oral
Subject Nebivolol Other / unclassified 20 mg Oral